Patients with mutations in the thyroid hormone receptor ␤ (TR␤) gene manifest resistance to thyroid hormone (RTH), resulting in a constellation of variable phenotypic abnormalities. To understand the molecular basis underlying the action of mutant TR␤ in vivo, we generated mice with a targeted mutation in the TR␤ gene (TR␤PV; PV, mutant thyroid hormone receptor kindred PV) by using homologous recombination and the Cre͞loxP system. Mice expressing a single PV allele showed the typical abnormalities of thyroid function found in heterozygous humans with RTH. Homozygous PV mice exhibit severe dysfunction of the pituitary-thyroid axis, impaired weight gains, and abnormal bone development. This phenotype is distinct from that seen in mice with a null mutation in the TR␤ gene. Importantly, we identified abnormal expression patterns of several genes in tissues of TR␤PV mice, demonstrating the interference of the mutant TR with the gene regulatory functions of the wild-type TR in vivo. These results show that the actions of mutant and wild-type TR␤ in vivo are distinct. This model allows further study of the molecular action of mutant TR in vivo, which could lead to better treatment for RTH patients.
T he thyroid hormone 3,3Ј,5-triiodo-L-thyronine (T3) regulates growth, development, and differentiation. Its actions are mainly mediated through thyroid hormone receptors (TRs), which are ligand-dependent transcription factors (1, 2) . Three ligand-activated TR isoforms have been identified, TR␣1, TR␤1, and TR␤2, which are derived from the TR␣ and TR␤ genes, respectively. Each TR isoform has a unique developmental and tissue-specific expression (1, 2) . TR binds to specific DNA sequences known as thyroid hormone response elements (TRE) in the promoter regions of T3 target genes. The transcriptional activity of TR depends not only on the types of TRE but also on a host of coregulatory proteins (3) .
RTH is a syndrome characterized by reduced sensitivity of tissues to the action of thyroid hormone. This condition is characterized by elevated levels of circulating thyroid hormones associated with normal or high levels of serum thyroidstimulating hormone (TSH) (4) . The most common form of RTH is familial with autosomal dominant inheritance (4) . Patients are usually heterozygotes with only one mutant TR␤ gene, and the symptoms are mild. Moreover, clinical manifestations are variable among families with RTH and also among affected family members. Some of the clinical features that have been reported include goiter, short stature, decreased weight, tachycardia, hearing loss, attention deficit-hyperactivity disorder, decreased IQ, and dyslexia (4) . One single patient homozygous for a mutant TR␤ has been reported (5) . This patient displayed a complex phenotype of extreme RTH with very high levels of thyroid hormone and TSH. Most TR␤ mutants derived from RTH patients have reduced T3-binding affinities and transcriptional capacities. These TR␤ mutants exhibit a dominant-negative effect when cotransfected with wild-type TRs (6, 7) . TR␤ mutants that have defects in the interaction with corepressors and coactivators have also been reported (8, 9) .
Several transgenic mouse models expressing TR␤1 mutants have been developed, with the aim of understanding the mechanisms of action of TR␤1 mutants in vivo (10) (11) (12) (13) (14) . However, these mouse models were generated by using heterologous promoters resulting in mild phenotypes (10, 11, 14) and the expression of the mutants restricted to specific organs (11) (12) (13) (14) . The restrictive expression prevents comprehensive understanding of the action of TR␤1 mutants in a physiological context. We therefore generated mice with a targeted TR␤ mutation (mutant PV) by using homologous recombination and the Cre͞loxP system. PV was derived from a patient with severe RTH characterized by elevated thyroid hormone levels accompanied by normal TSH, short stature, goiter, and tachycardia (15) . PV has an unusual mutation in exon 10, a C-insertion at codon 448, which produces a frameshift of the carboxyl-terminal 14 amino acids of TR␤1 (15) . This naturally occurring mutation was chosen for two reasons. First, in vitro characterization of PV mutant showed completely lost T3-binding and transactivation activities. PV also strongly interferes with the transactivation activity of wild-type TRs in vitro. Therefore, this TR␤ mutant is more likely to produce phenotypic changes in the mouse. Second, unlike the missense mutations or single amino acid deletion of TR␤ found in other patients, this unique frame-shifted mutated sequence is immunogenic, for which high-affinity specific antibodies have been developed (16) . These antibodies should allow us to ask questions such as whether there is a correlation of the severity of RTH with the level of expression of mutant protein in affected tissues.
The present study shows that consistent with the findings in RTH patients, the pituitary-thyroid axis was mildly impaired in heterozygous TR␤ PV/ϩ mice and severely affected in homozygous TR␤ PV/PV mice. TR␤ expression patterns, demonstrating the in vivo interference of the mutant TR␤ with the gene regulatory functions of the wild-type receptors.
Materials and Methods Preparation of PV Mutant Mice.
A TR␤ mouse genomic clone was isolated from an ES-129 P1 Library (Genome Systems, St. Louis) by using primers specific for the TR␤ gene. After mapping the genomic sequences in the regions of exons 8, 9, 10 and the down-stream sequences of exon 10, a 17.5-kb targeting vector was constructed (see Fig. 1A ). A PV mutation site was generated in exon 10 with a C insertion at the coding nucleotide position 1642. In addition, a BamHI site was introduced at the coding nucleotides 1668-1673 without changing the amino acid sequence of the PV mutant. The neomycin resistance gene (NeoR), flanked by two LoxP sequences, was placed 1 kb downstream of the polyA site. The thymidine kinase gene (TK) was placed at the 3Ј terminus of the targeting vector. The lengths of the 5Ј and 3Ј arms were 5.4 kb and 5.6 kb, respectively.
The targeting vector was linearized by XbaI digestion and transfected (25 g ) into the TC-1 embryonic stem cells (17) . Recombinant clones were treated with 400 g͞ml G418 for positive selection and 2 M gancyclovir for negative selection. Seven recombinant clones were identified by Southern blotting analysis. The clones were microinjected into C57BL͞6J blastocysts to produce chimeras, which were crossed with NIH Black Swiss mice to establish germ-line transmission (18) . Mice harboring the targeted PV mutation and the NeoR gene are designated as TR␤PVNeoR mice (Fig. 1C) .
TR␤PVNeoR mice were genotyped by Southern blotting analyses and͞or PCR by using two sets of primers. For the identification of the wild-type allele, the sequence of the 5Ј-primer (W5) is: 5Ј-TCCCCAAGCCAGCATCCCGACC, and the 3Ј-primer (W3) is: 5Ј-CGGGCAAATCCTTACCTGG. For the identification of the mutant allele, the 5Ј-mutant primer (M5) is: 5Ј-TGCAGTGGCGATGGCATC, and the 3Ј-primer (M3) is: 5Ј-CTGACCGCTTCCTCGTGCTTTACG. PCR reactions were carried out for 35 cycles (94°C, 30 sec; 59°C, 30 sec; 74°C; 30 sec for the determination of the wild-type allele) (94°C, 30 sec; 63°C, 30 sec; 74°C; 30 sec for the mutant allele) in a buffer containing MgCl 2 by using TaKaRa EX-Taq polymerase (Intergen, Purchase, NY).
To delete the NeoR gene from the targeted locus in vivo, TR␤PVNeoR mice (Fig. 1C) were crossed with homozygous EllaCre transgenic mice (19) . The resulting offspring were genotyped by Southern blot and PCR analyses by using primers W5 and W3. Mice harboring the targeted PV mutation, but without the NeoR gene, are designated as TR␤ PV/PV and TR␤ PV/ϩ for the homozygous and heterozygous mutant mice, respectively.
Determination of the Expression of PV Mutant RNA in Tissues by
Reverse Transcription-PCR (RT-PCR). Total RNA was prepared by using Trizol Reagent (Life Technologies, Rockville, MD). RT-PCR was carried out by using poly(dT) as a primer for cDNA synthesis by using SuperScript II reverse transcriptase (Life Technologies). Fragments (688 bp) from the wild-type TR or (689 bp) from the mutant PV were amplified in the presence of 5Ј-primer (primer N): 5Ј ATGGGGAAATGGCAGTGACAC-GAG and 3Ј-primer (primer C): 5Ј-TGGGAGCTGGTGAT-GACTTCGTGC by using Taq DNA polymerase (PerkinElmer). The mutant PV sequence contained a BamHI site that was not present in the mouse endogenous TR␤ gene. PCR products were digested with BamHI to yield two 380-and 309-bp fragments for mutant PV, as analyzed by gel electrophoresis.
Northern Blot Analyses. Total RNA (5-10 g) was used for Northern blot analysis. After electrophoresis, RNA was transferred onto membranes (Hybond-Nϩ, Amersham Pharmacia), which were hybridized with appropriate probes. cDNA clones for TSH␣, TSH␤, growth hormone (GH), malic enzyme (ME), spot 14, and 5Ј-deiodinase I (5Ј-DI-I) were labeled with [␣-32 P]dCTP by using a random primer hexamer protocol. For quantification, the intensities of the mRNA bands were normalized against the intensities of GAPDH mRNA (n ϭ 3). The blots were stripped and rehybridized with a 32 P-labeled GAPDH cDNA. Quantifi- cation was performed by using the Molecular Dynamics Phosphor-Imager (Molecular Dynamics).
Hormone Assays and Determination of Serum Cholesterol. Serum levels [total L-thyroxine (T4) and T3] were determined by using Gamma Coat T4 or T3 assay RIA kit (DiaSolin, Stillwater, MN) according to the manufacturer's instructions. TSH levels in serum were measured as described (20) .
Histology and Immunohistochemistry. Thyroid glands were fixed in 10% neutral buffered formalin and subsequently embedded in paraffin. Five-micrometer-thick sections were prepared and stained with hematoxylin and eosin for microscopic examination.
Pituitaries from TR␤ PV/PV mice and wild-type littermates were fixed in 10% formalin in PBS for 2 h at 23°C, dehydrated, and embedded in paraffin. Five-micrometer-thick sections were deparaffinized in xylene, washed in ethanol, then treated with antigen unmasking solution (Vector Laboratories) and heated in a microwave oven for 5 min. The sections were then blocked in 1% BSA in PBS for 30 min at 23°C, followed by sequential incubations in rabbit anti-mouse TSH antiserum [1:1,000 dilution in BSA-PBS; Biogenesis (Bournemouth, U.K., catalogue no. 8922-6009)] for 30 min at 23°C, washed with PBS, then incubated with affinity-purified goat anti-rabbit IgG conjugated to horseradish peroxidase (Jackson ImmunoResearch). After washing in PBS, the sections were incubated in diaminobenzidine substrate solution (10 min, 23°C) followed by dehydration and mounting under cover slips without counterstains. Unstained sections were then examined by using bright-field as well as phase-contrast microscopy, and digital images were captured from these sections by using a ϫ20 objective and a Dage 300 CCD camera with a Zeiss Axioplan 2 microscope. These images were then printed, and nuclei of all cells in the field were counted by using the phase contrast image. The cells showing TSH labeling were then counted in the parallel bright-field image of the same field. The total numbers of cells counted for the pituitaries from the TR␤ PV/PV and wild-type mice were 866 and 655, respectively. Data Analysis. All data are expressed as mean Ϯ SE. Statistical analyses used the student's t test, and P Ͻ 0.05 was considered significant. Fig. 1 A. Positive embryonic stem (ES) clones were identified by using both internal and external probes ( Fig.  1 B and C) . BamHI digests of the genomic DNA from two positive clones revealed 12.5-, 10.2-, and 4.3-kb fragments when hybridized with the internal probe encompassing the PV mutation site in exon 10 (data not shown), whereas the control showed the expected 12.5-kb band (data not shown). When the EcoRV digests of the same positive ES clones were hybridized with the external probe, an additional 20-kb fragment was detected together with the 25-kb fragment derived from the wild-type allele (data not shown). These results indicate that the PV mutation was correctly targeted onto the TR␤ gene locus.
Results

Generation of Mice with Targeted TR␤ Mutant PV. The targeting vector is shown in
Mice carrying the TR␤PVNeoR gene (Fig. 1C) were identified by PCR by using DNA extracted from tails. By using primers for detection of mutant genes (M5 and M3; Fig. 1E-a Upper) or wild-type (W5 and W3; Fig. 1E-b Upper), typical results are shown in Fig. 1E-a and b Lower, respectively. The size of PCR products was 757 bp (lanes 3, 4, 6-8 from different mice; Fig.  1E -a Lower) and 452 bp (lanes 2, 3, 5, and 8; Fig. 1E-b Lower) from the mutant and wild-type genes, respectively.
Northern blot analyses of PV gene expression in TR␤ PV/ϩ NeoR heterozygous and TR␤ PV/PV NeoR homozygous mice (Fig. 1C) indicate that the expression of the PV mutant allele was repressed as compared with the wild-type TR␤ allele (data not shown). Because the NeoR gene was flanked by two loxP sequences in the targeted locus ( Fig. 1 A and C) , it was possible to delete the NeoR gene in vivo by crossing the TR␤ PV/PV NeoR homozygous mice with an Ella-Cre mice (19) . PCR analysis by using primers W5 and W3 (Fig. 1F) yielded a 546-bp fragment indicative of the removal of the NeoR gene (see Fig. 1 B-D) . Mice with the final targeted locus [without NeoR gene (Fig. 1D) RT-PCR was used to assess the expression of the PV mutant allele at the RNA level. Primers flanking the mutated exon 10 were used, and the resultant cDNA was digested with BamHI ( Fig. 2A Upper) . The cDNA derived from the mutant allele yielded two fragments with sizes 380 and 309 bp, whereas a 688-bp fragment was obtained from the wild-type mRNA. 3 and 6) , respectively. This analysis shows that PV allele was expressed in the cerebrum, cerebellum, pituitary, heart, muscle, white adipocytes, lung, spleen, and kidney (data not shown), indicating that the PV mutant allele was detected in expected T3 target tissues.
The expression of the PV allele in the liver was further confirmed by Northern blot analysis by using a cDNA probe specific to the TR␤ gene (Fig. 2B) . Lanes 7-9 (from three mice) indicate that the level of the transcription of TR␤PV gene in the TR␤ PV/PV mice was not significantly different from those in the TR␤ PV/ϩ (lanes 4-6 for three mice) and in the wild-type TR␤ ϩ/ϩ littermates (lanes 1-3 for three mice). Similarly, expression of the PV and wild-type TR␤ allele were similar in the heart and brain (data not shown). These findings indicate that the expression of the TR␤PV gene was not affected by the presence of the PV mutation.
Resistance to Thyroid Hormone Action on the Pituitary-Thyroid Axis.
Consistent with findings in heterozygous patients with the common form of RTH, the mean total T4 (TT4) concentration in TR␤ PV/ϩ mice was 8.6 Ϯ 0.4 g͞dl (n ϭ 9), which is 2.5-fold higher than that in the wild-type mice (3.5 Ϯ 0.1 g͞dl; n ϭ 22) (Fig. 3A) . The 15-fold increase in the circulating TT4 (51 Ϯ 3.6 g͞dl; n ϭ 17) observed in the TR␤ PV/PV mice was similar to that observed in the single patient homozygous for a mutant TR␤ gene (5).
The serum total T3 (TT3) concentration was also increased in TR␤PV mice. (Fig. 4B) vs. wild-type mice (Fig. 4 A) and extensive hyperplasia of the epithelium in TR␤ PV/PV mice (Fig. 4C) .
Stimulation of TSH secretion also reflected the severity of RTH (Fig. 5A) . In TR␤ PV/ϩ mice, TSH was 2.1-fold higher (121.9 Ϯ 24.8 microunits͞ml; n ϭ 29) as compared with the wild-type mice (58 Ϯ 8.9 microunits͞ml; n ϭ 21). These results indicate that the pituitary is resistant to the action of thyroid hormone because TR␤ PV/ϩ mice had 2.5-fold higher TT4 and 2-fold elevated TT3. A remarkable resistance was observed in the TR␤ PV/PV mice, showing a 412-fold higher serum TSH level (23,887 Ϯ 4,408 microunits͞ml; n ϭ 7) in the presence of 15-and 9-fold increase in serum TT4 and TT3 levels, respectively. Again, similarly extraordinary increase (Ϸ400-fold the normal) in the level of serum TSH was noted in the patient homozygous for a mutated TR␤ gene (5) .
We also examined whether the distribution of TSH secreting cells in the pituitary was affected by the expression of the PV mutant (Fig. 5B) . By using an anti-TSH antibody, we found that the percentages of positively staining cells were 11.29 Ϯ 0.76 (n ϭ 866), 10.7 Ϯ 2.0 (n ϭ 751), and 19.31 mice also exhibited a reduced growth spurt by 25-40% during the age 3-7 weeks (data not shown). However, no significant differences in pup weights and growth rates were detected between TR␤ PV/ϩ and TR␤ ϩ/ϩ mice (data not shown).
Alteration in the Expression Patterns of T3-Target Genes in Tissues of
TR␤PV Mice. As a first step to understand the molecular action of PV in vivo, we evaluated the expression of T3 target genes in the tissues of TR␤PV mice. Fig. 7A shows the expression of TSH and GH mRNA in the pituitary gland. TSH consists of two polypeptides, the TSH-specific ␤ subunit and the common ␣-glycoprotein subunit (␣-SU; also a subunit for gonadotropins), whose expression is suppressed by T3. However, despite the high circulating thyroid hormone levels, Northern blot analysis indicates that ␣-SU mRNA levels in the pituitaries of TR␤ PV/PV and TR␤ PV/ϩ mice were 60-and 1.7-fold higher than that of the wild-type mice (Fig. 7A) . A lesser but significant effect of the PV mutant on the expression of the TSH␤ gene was also observed (Fig. 7A) . The TSH␤ mRNA level in the pituitaries of TR␤ PV/PV mice was 2.7-fold higher than that in the wild-type mice. The TSH␤ mRNA level in the TR␤ PV/ϩ mice was not repressed as it should be by the elevated thyroid hormone levels, suggesting a reduced hormone-mediated repression of TSH␤ mRNA in the presence of PV. The latter results clearly indicate the interference of PV mutant with the gene regulatory function of the wild-type receptors on the expression of these ␣-SU and TSH␤ genes, albeit more pronounced for ␣-SU gene.
We further carried out Northern blot analyses of the positively T3-regulated genes in the pituitary. As shown in Fig. 7A , instead of being activated by the presence of the high circulating thyroid hormone levels, the expression of GH in the pituitaries of TR␤ PV/PV mice was repressed to 20% of that seen in the wild-type mice. The GH mRNA level in the TR␤ PV/ϩ mice was not increased compared with the wild-type mice, showing a reduced GH mRNA response to the elevated thyroid hormone levels resultant from the presence of one single PV allele. Taken together, these results indicate that the response to thyroid hormone of both positively and negatively T3-regulated genes is attenuated in the pituitary of TR␤PV mice.
The positively T3-regulated genes in the liver of TR␤PV mice also show reduced expression. As shown in Fig. 7B , the expression of ME, S14, and 5Ј-DI-I genes was reduced to 0.2, 0.3, and 0.8 in TR␤ PV/ϩ mice, respectively, compared with wild-type mice. The expression of ME and S14 mRNA was further reduced in the TR␤ PV/PV mice (decreased to 0.3 and 0.2, respectively). No 5Ј-DI-I mRNA was detected in TR␤ PV/PV mice (Fig. 7B) . These results indicate that the expression of PV gene dampened the magnitude of the T3-mediated responses of target genes in different tissues. These findings are in contrast to that found in mice lacking TR␤ (TR␤ Ϫ/Ϫ ), in which no changes in the expression of ME genes were detected (22) .
Discussion
Consistent with the findings in heterozygous patients with RTH, TR␤ PV/ϩ mice exhibited mild impairment in the pituitarythyroid axis. TR␤ PV/ϩ mice had a 2.1-fold elevated TSH despite 2-to 3-fold higher thyroid hormone levels as compared with TR␤ ϩ/ϩ mice. Corresponding increases in serum TSH, T4 and T3 in humans with RTH are on the average of 1.7-, 2.3-, and 2.5-fold, respectively (4). The thyroid glands showed enlarged follicles, and the development of bones was delayed. In TR␤ PV/PV mice, more extensive and pronounced abnormalities were observed. A severe resistance to the action of thyroid hormone in the pituitary was revealed by an extraordinarily high TSH level (412-fold increase) despite 9-to 15-fold increases in circulating T3 and T4 concentrations, respectively. The increases are also compatible with those reported in the single patient homozygous for a mutant TR␤ (5). The thyroid gland exhibited extensive hyperplasia and an 18-fold increase in size. The growth in TR␤ PV/PV mice was severely impaired, with a Ϸ17-23% reduction in weight gain and a Ϸ10% decrease in the lengths of long bones. These abnormalities are reminiscent of the findings in the patient with homozygous mutated TR␤ alleles (5). These results indicate that the mouse with a targeted PV mutation described in the present study is an accurate model for the study of RTH. In contrast to the previously reported transgenic mice (10) (11) (12) (13) (14) , the present mouse model provides an opportunity for future in-depth analysis of the molecular basis of RTH, which has not been possible in humans. 
Fig. 7.
The expression of T3-target genes in TR␤PV mice was altered. Total RNA was isolated from the pituitaries and liver of mice (three for each group of 8-week-old male mice). The intensities of the bands were quantified by using a Molecular Dynamics PhosphorImager. The levels of expression of both genes were normalized by using GAPDH mRNA. The mean values of three experiments are shown and expressed as the fraction (fold) change from the value in the TR␤ ϩ/ϩ mice.
Although the mild impairment in the thyroid-pituitary axis of TR␤ PV/ϩ mice is similar to that exhibited by the mice lacking TR␤, there are clear differences in the phenotypes between TR␤ PV/PV and TR␤ Ϫ/Ϫ mice (21) . The latter have neither severe dysfunction of the pituitary-thyroid axis nor impairment in weight gain and bone development. This study demonstrates that in mouse as in human, the effects of absence of TR␤ are distinct from those of the presence of a mutant TR␤. The present study shows that PV interferes with gene regulatory functions of the wild-type receptors in vivo (Fig. 7  A and B) . Despite higher levels of thyroid hormone in TR␤ PV/PV mice, the responses of T3-regulated genes are attenuated. Thus, PV attenuated the expression of genes positively regulated by thyroid hormone including the GH gene in the pituitary and the ME, S14, and 5Ј-DI-I in the liver. The expression of TSH mRNAs was activated, instead of being repressed by high T3 and T4, as demonstrated in hypothyroid mice treated with thyroid hormones (23) . However, in contrast to that observed in hypothyroid mice (23, 24) , the up-regulation of ␣-SU mRNA was more pronounced than TSH␤ mRNA in TR␤PV mice. At present, it is not clear whether this was because of T3-independent functions and/or the genespecific actions of PV.
Several mechanisms, however, have been proposed to explain the interference of the mutant TR␤ with the gene regulatory functions of the wild-type receptors: (i) competition for binding to TRE; (ii) exhaustion of limited transcription factors; or (iii) formation of inactive wild-type/mutant heterodimers on TRE. On the basis of the available in vitro biochemical evidence, the mechanism of competition of the wild-type TRs with mutants for binding to TRE is currently favored (mechanism i) (7, 25) . However, the present in vivo data suggest that the possibility of formation of inactive wild-type͞mutant heterodimers on TRE is also a viable mechanism (mechanism iii). In TR␤ PV/ϩ mice, with the presence of one copy of TR␤ (from the remaining one wild-type allele) and TR␣1 (from two TR␣ alleles), the expressed PV receptor probably preferentially forms inactive TR␤͞PV heterodimers on the TREs of T3 target genes. Detailed biochemical analyses have shown that mutant PV forms inactive heterodimers with wild-type TR␤ or TR␣1 and that the former is preferred because of a higher affinity in the dimer formation (26) . The mild phenotype exhibited in the pituitary-thyroid axis of the TR␤ PV/ϩ mice as a result of the antagonism of the TR␤-mediated functions by the preferential formation of inactive TR␤͞PV heterodimers is reminiscent of the phenotype seen in the mice lacking TR␤ (21) . The severe phenotype observed for the TR␤ PV/PV mice most likely represents a combination of the loss of both TR␤-and TR␣1-mediated functions. The former is because of the loss of the two wild-type TR␤ alleles, and the latter is because of the interference of PV mutant on the functions of TR␣1, presumably via the formation of inactive TR␣1͞mutant heterodimers in the absence of TR␤1 proteins. This hypothesis is supported by a similar degree of severe impairment in the pituitary-thyroid axis seen in mice deficient in both TR␣ and ␤ (TR␣ (27, 28) and TR␤ PV/PV mice are totally different. The former is because of the lack of receptor alleles (27, 28) , and the latter is because of the interference of the mutant receptor with the functions of wild-type receptors. Before all of the affected thyroid hormone target organs are evaluated and compared, it is premature to conclude that all other phenotypes exhibited by these two mouse models will be similar. It is entirely possible that the effects of mutant receptor in vivo could also manifest as ''gain of function,'' which could contribute to the phenotype seen in the TR␤PV mice. Therefore, future analyses and comparison of the phenotypes of these two mouse models should shed light on the mechanisms of actions of the wild-type and mutant receptors.
